Mid-Term Results of an Unsupported Body Fenestrated Graft for Treating Thoracoabdominal and Suprarenal Aneurysms

This study demonstrates that a strategy using the Anaconda Fenestrated endograft provides acceptable efficacy and safety in the treatment of SRAA and TAA. Despite a high reintervention rate, mid-term survival, and target-vessel patency support the use of this endograft as a valid treatment option for these aneurysms.Clinical ImpactThis study reports the outcomes of 57 patients treated for suprarenal and thoracoabdominal aneurysms using the Anaconda unsupported fenestrated stent graft, combined with thoracic modules when necessary. Mid-term survival and target vessel patency were acceptable, with no indication of inferior performance compared to established platforms. While the reintervention rate warrants caution, these findings support the Anaconda fenestrated system as a potential alternative for complex aneurysms. Larger studies with extended follow-up are needed to better identify patients who may benefit from an unsupported design and to confirm its long-term durability.